<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480568</url>
  </required_header>
  <id_info>
    <org_study_id>018-038</org_study_id>
    <nct_id>NCT03480568</nct_id>
  </id_info>
  <brief_title>Alirocumab in Patients on a Stable Dialysis Regimen</brief_title>
  <official_title>A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      12-week study of the efficacy and safety of alirocumab in patients maintained stably on
      hemodialysis or peritoneal dialysis. Measures of cholesterol levels, drug levels, PCSK9
      levels, routine chemistry and cell counts, and biomarkers will be obtained at baseline and at
      weeks 4, 8, 10 and 12 weeks. Safety events will be obtained throughout the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective: The objective of this trial is to demonstrate the efficacy of alirocumab
      150 mg every 2 weeks over 12 weeks on cholesterol levels.

      Secondary objective: To assess the safety of treating chronic dialysis patients with
      alirocumab 150 mg subcutaneously every 2 weeks for 12 weeks.

      Secondary objective: To demonstrate the efficacy of alirocumab 150 mg every 2 weeks over 12
      weeks on biomarkers.

      Exploratory objective: To assess alirocumab drug levels in subjects maintained on
      hemodialysis and peritoneal dialysis.

      Methodology: Open-label, nonrandomized study

      Number of patients Ten patients maintained on stable hemodialysis for a minimum of 3 months
      and ten patients maintained on stable peritoneal dialysis for a minimum of 3 months

      Test product: alirocumab 150 mg

      Mode of administration: administered subcutaneously

      Dosing interval: every 2 weeks

      Duration of treatment: 12 weeks

      Primary endpoint: Levels of LDL-cholesterol at 12 weeks

      Secondary endpoints: Levels of total cholesterol, triglycerides, apoprotein B, Cystatin-C,
      fibrinogen, hsCRP, IL-6, NGAL, NT-proBNP, soluble CD40 ligand, troponin T, VCAM

      Safety criteria: Adverse events, Incidence and intensity of AE, including serious AE (SAE),
      Withdrawal from study medication due to AE, Clinical relevant new findings or worsening of
      existing conditions physical examination, Clinically relevant changes in laboratory
      measurements from baseline
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2018</start_date>
  <completion_date type="Anticipated">September 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 5, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-label, nonrandomized study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in LDL cholesterol levels</measure>
    <time_frame>Baseline, 4 ,8, 12 weeks</time_frame>
    <description>Efficacy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HDL-cholesterol levels</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Efficacy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in apoprotein B levels</measure>
    <time_frame>Baseline, 4, 8, 12 weeks</time_frame>
    <description>Efficacy</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in PCSK9 levels</measure>
    <time_frame>Baseline, 4, 8, 10, 12 weeks</time_frame>
    <description>Efficacy</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in alirocumab drug levels</measure>
    <time_frame>Baseline, 4, 8, 10, 12 weeks</time_frame>
    <description>Efficacy</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hemodialysis</condition>
  <condition>Peritoneal Dialysis</condition>
  <condition>Hypercholesterolemia</condition>
  <condition>Atherosclerotic Disease</condition>
  <arm_group>
    <arm_group_label>alirocumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alirocumab 150 mg q 2 weeks for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alirocumab 150 MG/ML [Praluent]</intervention_name>
    <description>Cholesterol-lowering therapy</description>
    <arm_group_label>alirocumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients, ages 18 to 80 years.

          2. Written informed consent will be obtained before any study assessment is performed.

          3. Diagnosis of end-stage renal disease, maintained on dialysis, without dialysis
             complications, for at least 3 months.

          4. Patients may or may not have a diagnosis of atherosclerotic disease, such as a history
             of myocardial infarction (MI), cardiac percutaneous coronary intervention (PCI),
             coronary artery bypass (CABG) surgery, atherosclerotic transient ischemic attack (TIA)
             or cerebrovascular attack (CVA), or peripheral arterial disease (PAD).

          5. A total of 20 patients will be enrolled, 10 patients on hemodialysis and 10 patients
             on peritoneal dialysis.

        Exclusion Criteria:

          1. LDL-cholesterol level of &lt; 70 mg/dL.

          2. Any contraindication to subcutaneous injections.

          3. Patients on statin and/or ezetimibe therapy will have their cholesterol-lowering
             therapy continued as is without change during the time of the study.

          4. History of any allergy or intolerance to the study drug or drugs of the same class.

          5. A history of MI, PCI, CABG surgery, TIA, CVA, or PAD events within 3 months of
             enrollment.

          6. History of malignant cancer within the past 3 years, excepting basal cell skin cancer
             or cervical cancer in situ.

          7. Women of child-bearing potential, defined as all women physiologically capable of
             becoming pregnant, unless they are using highly effective methods of contraception
             during dosing of the drug and for 2 weeks after the last injection of the drug. Highly
             effective methods of contraception include:

               1. Total abstinence (when this is in line with the preferred and usual lifestyle of
                  the patient). Periodic abstinence (e.g., calendar, ovulation, symptothermal,
                  post-ovulation methods) and withdrawal are not acceptable methods of
                  contraception.

               2. Female sterilization (have had surgical bilateral oophorectomy with or without
                  hysterectomy) or tubal ligation at least 6 weeks before taking study treatment.
                  In case of oophorectomy alone, only when the reproductive status of the woman has
                  been confirmed by follow-up hormone level assessment.

               3. Male sterilization (at least 6 months prior to enrollment). For female patients
                  in the study, the vasectomized male partner should be the sole partner for that
                  patient.

               4. Use of oral (estrogen and/or progesterone), injected, or implanted hormonal
                  methods of contraception or placement of an intrauterine device or intrauterine
                  system or other forms of hormonal contraception that have comparable efficacy
                  (failure rate &lt; 1%), for example hormone vaginal ring or transdermal hormone
                  contraception.

               5. In case of use of oral contraception, women should have been stable on the same
                  pill for a minimum of 3 months before taking study treatment.

               6. Women are considered post-menopausal and not of child-bearing potential if they
                  have had 12 months of natural amenorrhea with an appropriate clinical profile
                  (e.g. age appropriate, history of vasomotor symptoms) or have had surgical
                  bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least
                  six weeks before enrollment.

          8. Pregnant or lactating women.

          9. Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or extraction of study drug, at investigator's discretion.

         10. History or evidence of drug or alcohol abuse within the last 12 months.

         11. Patients considered unsuitable for the study, including patients with psychiatric,
             behavioral or cognitive disorders, sufficient to interfere with the patient's ability
             to understand and comply with the protocol instructions or follow-up procedures.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cara East, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cara East, MD</last_name>
    <phone>214-820-2273</phone>
    <email>cara.east@bswhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Merielle Boatman</last_name>
    <phone>214-820-2273</phone>
    <email>merielle.boatman@bswhealth.org</email>
  </overall_contact_backup>
  <link>
    <url>https://www.niddk.nih.gov/health-information/health-statistics</url>
    <description>1. Kidney disease statistics for the United States. Kidney.niddk.nih.gov.</description>
  </link>
  <link>
    <url>https://pharm.ucsf.edu/kidney</url>
    <description>2. Statistics, The Kidney Project. Pharm.ucsf.edu/kidney/need/statistics.</description>
  </link>
  <link>
    <url>https://ghr.nlm.nih.gov/gene/PCSK9</url>
    <description>15. PCSK9 gene—genetics home reference. Ghr.nlm.nih.gov/gene/PCSK9.</description>
  </link>
  <results_reference>
    <citation>Collins AJ, Foley RN, Herzog C, Chavers BM, Gilbertson D, Ishani A, Kasiske BL, Liu J, Mau LW, McBean M, Murray A, St Peter W, Guo H, Li Q, Li S, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder J, Solid C, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers PW, Agodoa L. Excerpts from the US Renal Data System 2009 Annual Data Report. Am J Kidney Dis. 2010 Jan;55(1 Suppl 1):S1-420, A6-7. doi: 10.1053/j.ajkd.2009.10.009.</citation>
    <PMID>20082919</PMID>
  </results_reference>
  <results_reference>
    <citation>van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium, van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey AS, de Jong PE, Gansevoort RT, Levey A, El-Nahas M, Eckardt KU, Kasiske BL, Ninomiya T, Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Sacks F, Curhan G, Collins AJ, Li S, Chen SC, Hawaii Cohort KP, Lee BJ, Ishani A, Neaton J, Svendsen K, Mann JF, Yusuf S, Teo KK, Gao P, Nelson RG, Knowler WC, Bilo HJ, Joosten H, Kleefstra N, Groenier KH, Auguste P, Veldhuis K, Wang Y, Camarata L, Thomas B, Manley T. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011 Jun;79(12):1341-52. doi: 10.1038/ki.2010.536. Epub 2011 Feb 9.</citation>
    <PMID>21307840</PMID>
  </results_reference>
  <results_reference>
    <citation>Rogacev KS, Pinsdorf T, Weingärtner O, Gerhart MK, Welzel E, van Bentum K, Popp J, Menzner A, Fliser D, Lütjohann D, Heine GH. Cholesterol synthesis, cholesterol absorption, and mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2012 Jun;7(6):943-8. doi: 10.2215/CJN.05170511. Epub 2012 Mar 29.</citation>
    <PMID>22461539</PMID>
  </results_reference>
  <results_reference>
    <citation>6. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3:259-286.</citation>
  </results_reference>
  <results_reference>
    <citation>Chapter 2: Pharmacological cholesterol-lowering treatment in adults. Kidney Int Suppl (2011). 2013 Nov;3(3):271-279.</citation>
    <PMID>25019001</PMID>
  </results_reference>
  <results_reference>
    <citation>Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol. 2007 Jan;18(1):304-11. Epub 2006 Dec 13.</citation>
    <PMID>17167114</PMID>
  </results_reference>
  <results_reference>
    <citation>Shoji T. Serum lipids and prevention of atherosclerotic cardiovascular events in hemodialysis patients. Clin Exp Nephrol. 2014 Apr;18(2):257-60. doi: 10.1007/s10157-013-0871-z. Epub 2013 Sep 27. Review.</citation>
    <PMID>24072417</PMID>
  </results_reference>
  <results_reference>
    <citation>Wanner C, Krane V, März W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005 Jul 21;353(3):238-48. Erratum in: N Engl J Med. 2005 Oct 13;353(15):1640.</citation>
    <PMID>16034009</PMID>
  </results_reference>
  <results_reference>
    <citation>März W, Genser B, Drechsler C, Krane V, Grammer TB, Ritz E, Stojakovic T, Scharnagl H, Winkler K, Holme I, Holdaas H, Wanner C; German Diabetes and Dialysis Study Investigators. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol. 2011 Jun;6(6):1316-25. doi: 10.2215/CJN.09121010. Epub 2011 Apr 14.</citation>
    <PMID>21493741</PMID>
  </results_reference>
  <results_reference>
    <citation>Krane V, Schmidt KR, Gutjahr-Lengsfeld LJ, Mann JF, März W, Swoboda F, Wanner C; 4D Study Investigators (the German Diabetes and Dialysis Study Investigators). Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis. Kidney Int. 2016 Jun;89(6):1380-7. doi: 10.1016/j.kint.2015.12.033. Epub 2016 Feb 17.</citation>
    <PMID>26924051</PMID>
  </results_reference>
  <results_reference>
    <citation>Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30. Erratum in: N Engl J Med. 2010 Apr 15;362(15):1450.</citation>
    <PMID>19332456</PMID>
  </results_reference>
  <results_reference>
    <citation>Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairittichai U, Ophascharoensuk V, Fellström B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Grönhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendszus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011 Jun 25;377(9784):2181-92. doi: 10.1016/S0140-6736(11)60739-3. Epub 2011 Jun 12.</citation>
    <PMID>21663949</PMID>
  </results_reference>
  <results_reference>
    <citation>Everett BM, Smith RJ, Hiatt WR. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. N Engl J Med. 2015 Oct 22;373(17):1588-91. doi: 10.1056/NEJMp1508120. Epub 2015 Oct 7.</citation>
    <PMID>26444323</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>April 5, 2018</last_update_submitted>
  <last_update_submitted_qc>April 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alirocumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Will provide data upon request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

